The data about the potential impact of CD34_CAFs on BC clinic-pathologic parameters highlighted on the present paper, together with our findings about CD34_CAFs’ and αSMA_CAFs’ impact on the LB-HER2 BC molecular subtype may be considered the most original parts of the present study. The gene discussed is ERBB2; the disease is breast cancer.